Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichi Ando

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
Journal for Immunotherapy of Cancer|July 2, 2020
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective studyTomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 1, 2022
Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological AssociationTakahiro Yamaguchi, Yutaka Sugiyama, Toshiaki Tanaka, et al.
Nagoya Journal of Medical Science|March 20, 2024
Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancerKoki Nakanishi, Chie Tanaka, Mitsuro Kanda, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective studyTomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2014
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastomaYaping Shou, Douglas M Robinson, Dereck D Amakye, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2020
Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)Goro Nakayama, Nao Takano, Hiroya Taniguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
British Journal of Cancer|February 4, 2020
Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective studyNorio Okada, Shintaro Iwama, Takayuki Okuji, et al.
Clinical and Experimental Nephrology|October 25, 2023
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022Motoko Yanagita, Satoru Muto, Hiroyuki Nishiyama, et al.
Clinical and Experimental Nephrology|December 9, 2023
Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022Motoko Yanagita, Satoru Muto, Hiroyuki Nishiyama, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
Journal for Immunotherapy of Cancer|July 2, 2020
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective studyTomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 1, 2022
Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological AssociationTakahiro Yamaguchi, Yutaka Sugiyama, Toshiaki Tanaka, et al.
Nagoya Journal of Medical Science|March 20, 2024
Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancerKoki Nakanishi, Chie Tanaka, Mitsuro Kanda, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective studyTomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2014
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastomaYaping Shou, Douglas M Robinson, Dereck D Amakye, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2020
Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)Goro Nakayama, Nao Takano, Hiroya Taniguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
British Journal of Cancer|February 4, 2020
Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective studyNorio Okada, Shintaro Iwama, Takayuki Okuji, et al.
Clinical and Experimental Nephrology|October 25, 2023
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022Motoko Yanagita, Satoru Muto, Hiroyuki Nishiyama, et al.
Clinical and Experimental Nephrology|December 9, 2023
Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022Motoko Yanagita, Satoru Muto, Hiroyuki Nishiyama, et al.
Pageof 25